SAB Biotherapeutics Files 8-K with Warrant Details

Ticker: SABSW · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1833214

Sab Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySab Biotherapeutics, Inc. (SABSW)
Form Type8-K
Filed DateJan 28, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, warrants, corporate-actions

Related Tickers: SABS

TL;DR

SAB Biotherapeutics (SABS) filed an 8-K detailing warrants at $11.50 exercise price.

AI Summary

SAB Biotherapeutics, Inc. filed an 8-K on January 28, 2025, reporting on other events and financial statements. The company, formerly known as Big Cypress Acquisition Corp. until November 20, 2020, is incorporated in Delaware and based in Miami Beach, Florida. The filing includes details about warrants exercisable for common stock at an exercise price of $11.50 per share.

Why It Matters

This filing provides updated information on SAB Biotherapeutics' financial structure, specifically concerning outstanding warrants, which could impact future share dilution and investor decisions.

Risk Assessment

Risk Level: medium — The filing details financial instruments like warrants, which can introduce complexity and potential dilution, impacting the company's financial health and stock value.

Key Numbers

  • $11.50 — Warrant Exercise Price (Price at which warrants can be exercised for common stock.)

Key Players & Entities

  • SAB Biotherapeutics, Inc. (company) — Registrant
  • Big Cypress Acquisition Corp. (company) — Former company name
  • January 28, 2025 (date) — Date of report
  • November 20, 2020 (date) — Date of name change
  • $11.50 (dollar_amount) — Warrant exercise price

FAQ

What is the primary purpose of this 8-K filing for SAB Biotherapeutics, Inc.?

The primary purpose is to report on 'Other Events' and 'Financial Statements and Exhibits' as of January 28, 2025.

When did SAB Biotherapeutics, Inc. change its name from Big Cypress Acquisition Corp.?

The company changed its name from Big Cypress Acquisition Corp. on November 20, 2020.

What is the exercise price for the warrants mentioned in the filing?

The warrants are exercisable for one share of common stock at an exercise price of $11.50 per share.

In which state is SAB Biotherapeutics, Inc. incorporated?

SAB Biotherapeutics, Inc. is incorporated in Delaware.

What is the business address of SAB Biotherapeutics, Inc.?

The business address is 777 W 41st St, Suite 401, Miami Beach, Florida 33140.

Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-28 07:11:34

Key Financial Figures

  • $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 28, 2025, SAB Biotherapeutics, Inc., a Delaware corporation (the " Company " or " SAB "), issued a press release announcing the topline Phase 1 clinical results for SAB-142, the Company's human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (the " Release "). The Company will give a presentation (the " Presentation ") and discuss the results of the clinical trial during a live webinar event at 8:00 a.m. Eastern Time on January 28, 2025. Copies of each of the Release and Presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of the Company, dated January 28, 2025 99.2 Presentation of the Company, dated January 28, 2025 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: January 28, 2025 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.